July 15, 2024 – Baltimore, MD– OcuCell, an innovator in ocular cell therapy, is pleased to announce funding from AltruVision. Financial terms were not disclosed.
Established in 1957, AltruVision recovers over 1,500 eye donors per year, facilitating more than 1,000 corneal transplants annually. This partnership will enable OcuCell to continue advancing its Endo-Tek™ and Epi-Tek™ treatments, which are poised to revolutionize ocular cell therapy in the cornea space.
In addition to funding, AltruVision's President and CEO, Jim Quirk, will join the OcuCell Board of Directors. Sadeer Hannush, MD, will join the OcuCell Scientific Advisory Board.
“Dr. Hannush’s many years of leadership in the field of cornea are well known. He brings a commitment to ensuring that patients have access to the latest advancements in the field, coupled with his longstanding dedication to safety. His perspective will add additional depth to our already formidable group of clinicians and scientists,” said Co-Founder Ula Jurkunas, MD.
Mr. Quirk brings extensive leadership experience to the Board. He was recently elected to a two-year term as the Eye Bank Association of America (EBAA) Board Chair and served two terms as Co-Chair of the EBAA Accreditation Board, highlighting his technical and regulatory expertise.
“This investment aligns with our mission of improving vision through cornea transplantation, medical research, and education,” said Mr. Quirk. “We couldn’t be more excited about this new partnership, which will ensure AltruVision is helping to bring the most advanced forms of therapy to patients in need.”
As a leading innovator in ocular cell therapy, OcuCell is actively seeking to collaborate with industry stakeholders, research institutions, and healthcare partners as the company continues to revolutionize the treatment of corneal disease.
For media inquiries or to learn more about OcuCell’s pioneering advancements, please contact:
Chris Stoeger, President
(617)564-0399
Founded in 2022, OcuCell is a visionary biomedical company focused on leveraging cutting-edge cell culturing technologies to transform healthcare. By merging the fields of ophthalmology, biomedicine, research, and eye banking, we aim to bring groundbreaking medical solutions to patients and ophthalmic healthcare providers worldwide. We envision a world where every individual enjoys the gift of clear, vibrant vision throughout their lifetime.
Comments